May is Lupus Awareness Month!
https://pixabay.com/en/flower-rain-macro-detail-purple-641401/

May is Lupus Awareness Month!

Also known as systemic lupus erythematosus (SLE), lupus is a chronic autoimmune disorder in which the immune system mistakenly attacks different parts of the body such as the joints, kidneys,…

Continue Reading May is Lupus Awareness Month!
Lupus Nephritis: Belimumab Alongside Standard Treatment Improves Outcomes in East Asians
source: shutterstock.com

Lupus Nephritis: Belimumab Alongside Standard Treatment Improves Outcomes in East Asians

According to a story published in Healio, a recent study has concluded that a combination of standard treatment and belimumab produces better outcomes for patients of East Asian descent living with…

Continue Reading Lupus Nephritis: Belimumab Alongside Standard Treatment Improves Outcomes in East Asians

A New Standard for Corticosteroid Dosing for Childhood-Onset SLE with Proliferative Lupus Nephritis

Recently, an international group of pediatric rheumatologists and nephrologists met and created a consensus on a standard for a steroid-dosing regimen to treat childhood-onset systemic lupus erythematosus with proliferative lupus…

Continue Reading A New Standard for Corticosteroid Dosing for Childhood-Onset SLE with Proliferative Lupus Nephritis

Study Determines Cut-off Values for Biomarkers Which Can Increase Risk of Severe Renal Outcomes in Lupus Nephritis

A recent study published in Advances in Rheumatology has uncovered 2 potential biomarkers which could be used to predict which lupus nephritis (LN) patients are at the highest risk of severe renal…

Continue Reading Study Determines Cut-off Values for Biomarkers Which Can Increase Risk of Severe Renal Outcomes in Lupus Nephritis
Marketing Authorization Application Submitted to the EMA for Novel Lupus Nephritis Therapy
source: pixabay.com

Marketing Authorization Application Submitted to the EMA for Novel Lupus Nephritis Therapy

Aurinia Pharmaceuticals has just announced that Otsuka Pharmaceutical Europe Ltd. (OPEL), their licensing partner, has just filed a Marketing Authorization Application for an investigative therapy for lupus nephritis (LN) called…

Continue Reading Marketing Authorization Application Submitted to the EMA for Novel Lupus Nephritis Therapy
Benlysta Approved in Europe for Lupus Nephritis
https://pixabay.com/photos/hospital-infusion-hand-association-834157/

Benlysta Approved in Europe for Lupus Nephritis

  In early May 2021, pharmaceutical company GlaxoSmithKline shared that its therapy Benlysta (belimumab) was approved by the European Commission (EC) for expanded use in adult patients with lupus nephritis…

Continue Reading Benlysta Approved in Europe for Lupus Nephritis
Unmet Needs in the Treatment of Certain Glomerular Diseases
source: pixabay.com

Unmet Needs in the Treatment of Certain Glomerular Diseases

by Lauren Taylor from In The Cloud Copy Nephrologists worldwide have shown that there is a huge unmet need when it comes to the treatment of various glomerular diseases, in…

Continue Reading Unmet Needs in the Treatment of Certain Glomerular Diseases